Medical management of pancreatic neuroendocrine tumors in patients with MEN 1: case report

ObjectivesMultiple endocrine neoplasia type 1 (MEN-1) is a rare inherited autosomal dominant disease which manifests itself with at least one clinical scenario before 45 years of age. The value of somatostatin analogue therapy is unknown in the treatment of non-functioning pancreatic tumours and a f...

Full description

Saved in:
Bibliographic Details
Published in:Journal of diabetes and metabolic disorders 2022, Vol.21 (2), p.2009-2011
Main Authors: Mohajeri-Tehrani, Mohammad Reza, Ebrahimpur, Mahbube, Nasseri-Moghaddam, Siavosh, Tavangar, Seyed-Mohammad, Sani, Mahnaz Pejman, Zandi, Abdollah, Shadmehr, Mohammad Behgam
Format: Report
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ObjectivesMultiple endocrine neoplasia type 1 (MEN-1) is a rare inherited autosomal dominant disease which manifests itself with at least one clinical scenario before 45 years of age. The value of somatostatin analogue therapy is unknown in the treatment of non-functioning pancreatic tumours and a few studies have been published in this field. Case presentationWe report a young patient with MEN-1 with multiple gastric and pancreatic neuroendocrine tumors that was treated with the monthly injection of Sandostatin LAR before and After Distal Pancreatectomy and partial gastrectomy. ConclusionsNow she is well after four years of treatment with Sandostatin LAR.
ISSN:2251-6581
2251-6581
DOI:10.1007/s40200-022-01067-3